Trial Profile

MAINtenance Afinitor (MAIN-A): A randomized trial comparing maintenance aromatase inhibitors (AIs) + everolimus (Afinitor) vs. AIs in patients withHR+ metastatic breast cancer with disease control after first line chemotherapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Jul 2021 Primary endpoint (Progression free survival) has not been met, according to Results published in the European Journal of Cancer.
02 Jul 2021 Results published in the European Journal of Cancer.
02 Dec 2020 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com